THE MARKET

A worldwide need. A US-first plan.

Physicians everywhere face the same problem: too little time to review a full history and medication list before each visit. Tachyra is built for the United States first. The same physician-review model can apply in any health system with electronic records.

THE SIZE OF IT

Millions of physicians, and a growing market for decision support.

~17.6M

Physicians worldwide (2022 estimate).

Advance Study, drawing on World Health Organization data

1.03M

Active physicians in the United States, Tachyra’s first market (2024).

Association of American Medical Colleges

$3.9B

Projected global clinical decision support market by 2030, up from about $2.5B in 2025 (about 10% a year).

MarketsandMarkets

That market figure mostly counts today’s drug alerts and guideline tools built into hospital systems. AI that reviews the whole patient before the visit is a newer category, and North America is the largest region.

THE EXPANSION PATH

Prove it in the US, then grow in order of difficulty.

This round funds the United States only. International markets follow US validation.

United States

Pilot, validate and build revenue with US physician practices. The sole focus of this round.

Now

Canada, United Kingdom, Australia, New Zealand

English-speaking, aging populations, digitized records. Each needs its own regulatory clearance and record-system connections.

After US validation

Gulf private hospitals

Ready buyers of US health technology, working in English, often reached through a local distributor.

After US validation

European Union

A large market with medical-device, AI and privacy rules to meet, plus local languages.

Longer term

Asia and Latin America

The most physicians, reached through partners or licensing.

Longer term

WHAT CHANGES OUTSIDE THE US

The physician stays in charge everywhere. The details differ.

Drug data

Brand names and approved drugs vary by country, so medication checking uses country-specific drug databases.

Approvals

Each country decides how it regulates clinical decision support software, so each market gets its own review.

Pricing

Prices per physician are generally lower outside the US and the Gulf, so partners and licensing carry more of the growth there.

Built for the US first, with room to grow.

Tachyra Diagnostics is raising its seed round from accredited investors.

Investor information

Sources: Advance Study, “How Many Doctors Were in the World in 2022?” (WHO data); AAMC physician workforce key findings; MarketsandMarkets, Clinical Decision Support Systems outlook. Third-party market figures are estimates. Expansion plans are forward-looking and depend on funding, validation and regulatory review. This page is not an offer to sell securities; any offering is made only to verified accredited investors through the offering documents.